Compare
Inmune Bio, Inc. vs Entera Bio Ltd. vs AIM ImmunoTech Inc. vs Senti Biosciences Holdings, Inc.
| Latest fiscal year | Inmune Bio, Inc. INMB | Entera Bio Ltd. ENTX | AIM ImmunoTech Inc. AIM | Senti Biosciences Holdings, Inc. SNTI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $50.0K | $42.0K | $88.0K | $22.0K |
| Revenue growth (YoY) | +257.1% | -76.8% | -48.2% | n/a |
| Gross margin | n/a | 0.0% | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$45.93M | -$11.44M | -$13.96M | -$61.44M |
| EPS (Diluted) | -$1.86 | $0.25 | -$8.62 | -$2.73 |
| Operating cash flow | -$22.58M | -$7.37M | -$10.96M | -$43.44M |
| Free cash flow | -$23.62M | -$7.48M | n/a | -$43.64M |
| Cash & equivalents | $24.75M | $7.11M | $2.98M | $16.42M |
| Total assets | $32.35M | $15.99M | $5.78M | $51.22M |
| Total liabilities | $8.83M | $2.89M | $15.56M | $45.63M |
| Shareholders' equity | $23.52M | $13.10M | -$9.78M | $5.59M |
| Return on year-end equity | -195.3% | -87.3% | n/a | n/m |
| Shares outstanding | 26.59M | 46.18M | 3.07M | 30.88M |
Revenue, most recent five fiscal years
| Fiscal year | Inmune Bio, Inc. | Entera Bio Ltd. | AIM ImmunoTech Inc. | Senti Biosciences Holdings, Inc. |
|---|---|---|---|---|
| Latest | $50.0K Ended 2025-12-31 | $42.0K Ended 2025-12-31 | $88.0K Ended 2025-12-31 | $22.0K Ended 2025-12-31 |
| 1 year earlier | $14.0K Ended 2024-12-31 | $181.0K Ended 2024-12-31 | $170.0K Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $155.0K Ended 2023-12-31 | $0 Ended 2023-12-31 | $202.0K Ended 2023-12-31 | $1.98M Ended 2023-12-31 |
| 3 years earlier | $374.0K Ended 2022-12-31 | $134.0K Ended 2022-12-31 | $141.0K Ended 2022-12-31 | $3.29M Ended 2022-12-31 |
| 4 years earlier | $181.0K Ended 2021-12-31 | $571.0K Ended 2021-12-31 | $135.0K Ended 2021-12-31 | $2.29M Ended 2021-12-31 |